MYD88 L265P Mutation Analysis
Use
The MYD88 L265P Mutation Analysis is a qualitative real-time PCR assay used for detecting the MYD88 L265P mutation. This mutation is primarily found in Lymphoplasmacytic Lymphoma (LPL) cases, including Waldenström’s macroglobulinemia. Identifying this mutation assists in distinguishing LPL from other low-grade B-cell lymphoproliferative disorders which can have similar clinical presentations. The detection of this mutation is crucial for guiding treatment decisions, potentially involving chemotherapy or the use of rituximab.
Special Instructions
Frozen blood and bone marrow samples are not accepted. Extracted DNA for clinical testing must be isolated in a CLIA-certified laboratory or equivalent. All sample concentration and volume details must be provided for testing.
Limitations
Improper specimen labeling, insufficient sample volume, clotted specimens, and specimens beyond stability will lead to rejection. The mutation analysis is subject to change as per biopharma protocol requirements, and final turnaround times will be specified in the biopharma study contract.
Methodology
PCR-based (RT-PCR)
Biomarkers
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5mL
Minimum Volume
3mL
Container
EDTA preferred (NaHep accepted)
Storage Instructions
2°C to 8°C
Causes for Rejection
Improper specimen labeling; Insufficient sample volume; Clotted specimen; Specimens beyond stability; Insufficient DNA isolated
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 30 days |
| Frozen | Long Term |